Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis.

MLA

Govoni, Mirco, et al. “Sputum and Blood Transcriptomics Characterisation of the Inhaled PDE4 Inhibitor CHF6001 on Top of Triple Therapy in Patients with Chronic Bronchitis.” Respiratory Research, vol. 21, no. 1, Mar. 2020, p. 72. EBSCOhost, https://doi.org/10.1186/s12931-020-1329-y.

APA

Govoni, M., Bassi, M., Vezzoli, S., Lucci, G., Emirova, A., Nandeuil, M. A., Petruzzelli, S., Jellema, G. L., Afolabi, E. K., Colgan, B., Leaker, B., Kornmann, O., Beeh, K. M., Watz, H., & Singh, D. (2020). Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis. Respiratory Research, 21(1), 72. https://doi.org/10.1186/s12931-020-1329-y

Chicago

Govoni, Mirco, Michele Bassi, Stefano Vezzoli, Germano Lucci, Aida Emirova, Marie Anna Nandeuil, Stefano Petruzzelli, et al. 2020. “Sputum and Blood Transcriptomics Characterisation of the Inhaled PDE4 Inhibitor CHF6001 on Top of Triple Therapy in Patients with Chronic Bronchitis.” Respiratory Research 21 (1): 72. doi:10.1186/s12931-020-1329-y.